融资方面，南模生物当日融资买入403.02万元。当前融资余额6368.59万元，占流通市值的1.94%，融资 余额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，南模生物十大流通股东中，天弘医疗健康A（001558）位居第十 大流通股东，持股37.74万股，为新进股东。融通健康产业灵活配置混合A/B（000727）退出十大流通股 东之列。 融券方面，南模生物12月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 12月24日，南模生物涨0.86%，成交额2025.20万元。两融数据显示，当日南模生物获融资买入额403.02 万元，融资偿还446.37万元，融资净买入-43.35万元。截至12月24日，南模生物融资融券余额合计 6368.59万元。 分红方面，南模生物A股上市后累计派现3004.13万元。近三年，累计派现1000.47万元。 资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号，成立日期2000年9 月20日 ...

Core Viewpoint - Nanmo Biology focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Company Overview - The company utilizes gene editing technology to insert, delete, or modify endogenous genes, creating biological models that simulate specific physiological, pathological, and cellular characteristics of humans [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Core Viewpoint - Nanmo Biology (688265.SH) focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Group 1: Company Overview - The company utilizes gene editing technology to insert, delete, or modify specific DNA segments, creating biological models that simulate human physiological, pathological, and cellular characteristics [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Group 2: Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Group 1 - The core viewpoint of the news is that Nanmo Bio experienced a slight decline in stock price and had notable financing activities on November 11, indicating a high level of financing balance relative to its market value [1] - On November 11, Nanmo Bio's financing buy amount was 1.87 million yuan, while the financing repayment was 2.23 million yuan, resulting in a net financing buy of -0.36 million yuan [1] - As of November 11, the total financing and securities lending balance for Nanmo Bio was 67.73 million yuan, which accounts for 1.95% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Nanmo Bio was 6,687, an increase of 2.53% from the previous period, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Bio achieved an operating income of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to the parent company of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 3 - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, marking its entry as a new shareholder, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Nanmo Biological has seen a stock price increase of 5.09%, reaching 48.35 yuan per share, with a total market capitalization of 3.77 billion yuan [1] - Nanmo Biological, established on September 20, 2000, specializes in the research, production, and sales of genetically modified animal models, with its main business revenue composition being: standardized models 48.34%, model technical services 21.92%, model breeding 19.50%, customized models 9.34%, and others 0.91% [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biological, holding 377,400 shares, which is 0.48% of the circulating shares, with an estimated floating profit of approximately 883,200 yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, and has achieved a year-to-date return of 36.83% [2] Group 3 - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 41.15% and the worst being 40.68% [3]

Core Viewpoint - Nanmo Bio is a leading supplier of genetically modified animal models in China, providing critical technical support for the biopharmaceutical industry with a full industry chain service capability [1] Group 1: Business Performance - In Q3 2025, Nanmo Bio achieved a revenue of 303 million yuan, ranking 24th among 29 companies in the industry [2] - The company's net profit for the same period was 26.76 million yuan, placing it 19th in the industry [2] - Revenue breakdown: standardized models accounted for 48.34% (94.62 million yuan), model technical services for 21.92% (42.90 million yuan), model breeding for 19.50% (38.17 million yuan), customized models for 9.34% (18.29 million yuan), and other revenue for 0.91% (1.77 million yuan) [2] Group 2: Financial Ratios - As of Q3 2025, Nanmo Bio's debt-to-asset ratio was 10.38%, down from 11.82% year-on-year and significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The company's gross profit margin was 52.87%, an increase from 43.63% year-on-year and above the industry average of 37.70%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 2.53% to 6,687, while the average number of circulating A-shares held per shareholder decreased by 2.47% to 11,700 [5] - Tianhong Medical Health A became a new major shareholder with 377,400 shares, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [5] Group 4: Executive Compensation - The chairman, Fei Jian, received a salary of 500,000 yuan in 2024, an increase of 100,000 yuan from 2023 [4] - The company is controlled by Shanghai Dish Enterprises Management Consulting Co., Ltd., with Wang Mingjun and Fei Jian as the actual controllers [4]

Core Viewpoint - The company, Shanghai Nanfang Model Biology Technology Co., Ltd., is preparing for its 2024 annual general meeting, focusing on maintaining shareholder rights and ensuring orderly proceedings [1][2]. Meeting Details - The annual general meeting is scheduled for June 20, 2025, at 15:00, combining on-site and online voting methods [3][4]. - Shareholders must register and provide valid identification to participate in the meeting [2][3]. - The meeting will include discussions on various proposals, including the 2024 annual report and the board's work report [5][6]. Financial Performance - In 2024, the company achieved a revenue of approximately 381.24 million yuan, a year-on-year increase of 4.01% [8]. - The net profit attributable to the parent company was about 6.50 million yuan, marking a turnaround from a loss in the previous year [8][10]. - The company reported a significant increase in net cash flow from operating activities, amounting to approximately 71.56 million yuan, a 256.35% increase compared to the previous year [8][10]. Business Segments - The company experienced stable growth in its scientific research services, while industrial revenue saw a slight decline due to a challenging investment environment [10][13]. - Revenue from overseas markets grew by 31.88%, indicating successful expansion efforts [14]. Strategic Initiatives - The company plans to enhance its research and development capabilities, focusing on gene editing technologies and expanding its product offerings [20][21]. - There is an emphasis on improving customer relationship management and expanding the sales network, particularly in international markets [22][24]. Governance and Compliance - The board of directors is committed to adhering to relevant laws and regulations, ensuring effective governance and decision-making processes [8][18]. - The company has established specialized committees to assist in decision-making and oversight, ensuring compliance with corporate governance standards [16][18].